ADC Therapeutics ADCT Institutional Ownership

Ownership Summary

ADC Therapeutics SA (NYSE:ADCT) appears in 116 institutional 13F filings for the quarter ending March 2026.

• Their combined ownership stood at 48.8% of outstanding shares in March 2026, down from 768.9% in December 2025.
• They increased total shares held in ADC Therapeutics by 1.42% from last quarter, and the number of investors in ADCT increased 38.1% annually.
• Of these 116 funds, 71 grew their exposure to ADC Therapeutics, 28 cut back, and 17 maintained positions.
• In total, institutional investors held 75.22Mn shares in ADC Therapeutics as of March 2026, up by 1.05Mn shares quarter on quarter, and up 16.64Mn shares year over year.
• Redmile Group, LLC leads ownership in ADCT with 15.47Mn shares as of March 31, 2026, equal to 10.04% of outstanding shares.
• Top purchasers of ADCT stock for the quarter ending March 2026 included MILLENNIUM MANAGEMENT LLC (2.79Mn), EVENTIDE ASSET MANAGEMENT, LLC (2.34Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (1.03Mn), BlackRock, Inc. (823.44K), TWO SIGMA INVESTMENTS, LP (548.56K).
• Leading sellers of ADC Therapeutics shares for the quarter ending March 2026 were ORBIMED ADVISORS LLC (4.5Mn), Point72 Asset Management, L.P. (1.63Mn), Goldman Sachs Group Inc (1.63Mn), Blue Owl Capital Holdings LP (733.57K), Redmile Group, LLC (196.23K).
• Per Business Quant data, the top 10 holders of ADC Therapeutics for the quarter ending March 2026 are Redmile Group, LLC (15.47Mn), TCG Crossover Management, LLC (11.39Mn), BlackRock, Inc. (6.25Mn), EVENTIDE ASSET MANAGEMENT, LLC (5.7Mn), Nantahala Capital Management, LLC (5.6Mn), Morgan Stanley (3.81Mn), Point72 Asset Management, L.P. (3.38Mn), MILLENNIUM MANAGEMENT LLC (3.12Mn), Goldman Sachs Group Inc (1.65Mn), State Street Corp (1.57Mn).